Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NuPOWER: Nuwiq for perioperative management in haemophilia A patients on emicizumab prophylaxis
2022-502060-21-00Phase 4Authorised
- Sponsor
- Octapharma
- Start
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 4, open-label, single-arm trial of simoctocog alfa in hemophilia A, sponsored by Octapharma. Primary endpoint: Overall perioperative haemostatic efficacy of Nuwiq. Planned start Aug 2023; status: authorised.
02
Drugs
simoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2022-502060-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502060-21-00.